The roadmap outlines a path for accelerating the development of malaria vaccines.

Led by the World Health Organization, the world’s leading funders of malaria vaccine development have developed a global strategy to accelerate development of malaria vaccines.

This strategy, the Malaria Vaccine Technology Roadmap, has as its vision the development and licensing of safe and effective vaccines that prevent disease and death and that also prevent transmission of the malaria parasite to enable elimination and eventual eradication of the disease. The Malaria Vaccine Funders Group first published the roadmap in 2006 and updated it in 2013. 

The roadmap outlines a path toward an interim goal of developing and licensing a first-generation vaccine by 2015 that has a protective efficacy of more than 50 percent against severe disease and death and lasts longer than one year.

The roadmap also calls for the development of vaccines against the two types of malaria that pose the greatest threat around the world—Plasmodium falciparum malaria, which is predominant in Africa and causes the most deaths globally, and the more widespread Plasmodium vivax malaria, which is found in many countries outside of Africa.  
The roadmap outlines a path toward licensing vaccines targeting P. falciparum and P. vivax by 2030 and encompasses two objectives:
  • Developing malaria vaccines with protective efficacy of at least 75 percent against clinical malaria.
  • Developing malaria vaccines that reduce transmission of the parasite in order to substantially reduce the incidence of human malaria infection.